Roche的新测试确定了卵巢癌患者接受有针对性的治疗,标志着个人化癌症护理的一步。 Roche's new test identifies ovarian cancer patients for a targeted treatment, marking a step in personalized cancer care.

Roche在欧洲获得核准,进行新的诊断测试,确定有资格接受称为ELAHERE的定向治疗的卵巢癌患者。 Roche has received approval in Europe for a new diagnostic test that identifies ovarian cancer patients eligible for a targeted treatment called ELAHERE. 这一测试检测了大多数卵巢癌中表现过度的叶酸受体1蛋白质。 This test detects the folate receptor 1 protein, over-expressed in most ovarian cancers. 这种治疗是由AbbVie开发的,为抗白金抗卵巢癌患者提供了一个新的选择,与化疗相比,存活率有所改善。 The treatment, developed by AbbVie, provides a new option for patients with platinum-resistant ovarian cancer, showing improved survival rates compared to chemotherapy. 这项批准标志着在卵巢癌患者个人化保健方面迈出了重大一步。 The approval marks a significant step in personalized healthcare for ovarian cancer patients.